MiMedx price target lowered to $6 from $10 at Northland

Northland lowered the firm’s price target on MiMedx (MDXG) to $6 from $10 and keeps an Outperform rating on the shares. The firm is assuming a “conservative posture” with respect to near-term Wound Care segment performance, but argues that the market is “over-discounting near-term disruption” and says it still believes the long-term prospects of MiMedx’s Surgical segment remains strong.